Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma

NCT00169143 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Untreated CD20-positive Large B-cell Lymphoma

Interventions

DRUG: Rituximab + ACVBP regimen plus Pegfilgrastim
PROCEDURE: Autologous stem cell transplant

Sponsor

Lymphoma Study Association

Collaborators

[object Object]